Ambulatory Extracorporeal Membrane Oxygenation Use in Patients Listed for Lung Transplant

• Published in: ASAIO journal (1992) Vol. 70; no. 7; p. 625
• Main Authors: Trivedi, Jaimin R, Endo, Toyokazu, Sharma, Anya, Fox, Matthew P, Slaughter, Mark S, van Berkel, Victor H
• Format: Journal Article
• Language: English
• Published: United States 01.07.2024
• Subjects: Adult; Ambulatory Care - methods; Ambulatory Care - statistics & numerical data; Extracorporeal Membrane Oxygenation - methods; Extracorporeal Membrane Oxygenation - statistics & numerical data; Female; Humans; Lung Transplantation - methods; Lung Transplantation - statistics & numerical data; Male; Middle Aged; Retrospective Studies; Waiting Lists - mortality
• ISSN: 1538-943X
• DOI: 10.1097/MAT.0000000000002154

There has been an increase in the use of extracorporeal membrane oxygenation (ECMO) to bridge critically ill patients to lung transplant (LTX). This study evaluates how ambulatory status on ECMO affected waitlist and post-LTX outcomes. The United Network of Organ Sharing (UNOS) database was queried for patients aged of greater than or equal to 18 years and between 2016 and 2021 to identify pre-LTX patients supported by ECMO. The patients were classified in venous-arterial (VA) ECMO and veno-venous (VV) ECMO cohorts and further classified as ambulatory (AMB) and non-AMB (nAMB). Each cohort was controlled against the non-ECMO patients. Univariate statistical tests, as well as Kaplan-Meier survival curves, were used for analysis. The 90 day waitlist survival was the highest among the non-ECMO group (96%), but both AMB VV and VA groups had superior survival compared to the nAMB group (85% vs. 75%, 78% vs. 65%, p < 0.01). After adjusting for the median lung allocation score (LAS) (88) in the VV ECMO group, the waitlist survival was superior in the AMB VV ECMO compared to those not on ECMO (86% vs. 78%, p > 0.01). The 1 year post-LTX survival between non-ECMO and AMB VV ECMO was comparable (88% vs. 88%, p = 0.66). Ambulating patients or use of physical therapy while on ECMO can help improve lung transplant outcomes.